Skip to content

Multi-Day Evaluation of the TIVA Device

Multi-Day Evaluation of the TIVA Device

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02747147
Enrollment
160
Registered
2016-04-21
Start date
2016-04-12
Completion date
2016-12-07
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Collections Via Peripheral IV Catheter

Brief summary

Prospective, randomized, single-center study to evaluate the ability of the device to collect good quality blood samples from patients with peripheral IV access over the length of their stay.

Interventions

DEVICETIVA blood collection device

the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe

Sponsors

Velano Vascular, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient will be admitted to the BWH unit 15 for post-surgical care * Patient is at least 18 years old * Patient is willing and physically / cognitively able to sign a written consent form * Patient is willing and able to complete study questionnaires * Patient is NOT a prisoner

Exclusion criteria

* Active hemodialysis * Hemolytic disorders (e.g., sickle cell disease) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
% Aspiration reliabilityup to 4 days after PIV placementblood aspiration with the device is attempted once per day. The % of attempts that are successful will be reported across all attempts
% of Specimen hemolyzedup to 4 dayseach collected specimen will be analyzed for hemolysis. The hemolysis rate, or % of specimen that are hemolyzed will be reported over all collections.

Secondary

MeasureTime frameDescription
Avg PIV dwell - hours, mean, range1, 2, 3, and 4 calendar days after PIV placementnote hours between each PIV placement and removal for each patient. compare the the distribution of PIV dwell between the two arms

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026